New drug combo aims to match standard care in colorectal cancer battle
NCT ID NCT07595276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether a new drug called Enlituo, combined with chemotherapy (FOLFOX), works as well as the standard treatment Erbitux plus FOLFOX for people with advanced colorectal cancer that has specific genetic traits (RAS/BRAF wild-type and MSS/pMMR). About 608 adults will receive one of the two treatments every two weeks. The main goal is to see how many patients' tumors shrink within 16 weeks. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?